About Us

Who We Are

The Center for Innovative Phage Applications and Therapeutics (IPATH) was founded in the UC San Diego School of Medicine in June 2018 with seed funding from UC San Diego Chancellor Pradeep Khosla. Our goal is to pursue, through collaboration with researchers, companies and institutions around the world, new treatments for combating antimicrobial resistant diseases-focusing on bacteriophage (phage) therapy. We have treated and will continue to treat patients with life-threatening multi-drug resistant infections with phage therapy through the FDA's compassionate use program. We also strive to advance phage therapy into clinical trials so that it can be rigorously evaluated and if proven efficacious, become more widely available to combat the global superbug crisis. 

IPATH is a research and consultation program and we do not take over the care of patients who wish to pursue phage therapy. Our clinicians and staff are engaged as consultants to the treating physician(s) to advise on patient eligibility for phage therapy based on medical history and antibiogram results, support connection to phage testing and manufacturing facilities, and to offer guidance on the FDA’s (e/sp)IND application process.